Evidence map›Paper›PMID 35509030›Full record

ArticleBMC cancer2022

Digital phenotyping in young breast cancer patients treated with neoadjuvant chemotherapy (the NeoFit Trial): protocol for a national, multicenter single-arm trial.

Lidia Delrieu, Anne-Sophie Hamy, Florence Coussy, Amyn Kassara, Bernard Asselain, Juliana Antero, Paul De Villèle, Elise Dumas, Nicolas Forstmann, Julien Guérin and 10 more

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05011721 (Digital Phenotyping), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05011721 nacompletednot on this map

Digital Phenotyping (Physical Activity, Heart Rate, Sleep) in Young Breast Cancer Patients Treated With Neoadjuvant Chemotherapy

TypeinterventionalSponsorInstitut CurieRan2021 to 2025Enrolled300ConditionsBreast CancerArmsActivity tracker
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 1 country.

Lidia DelrieuResidual Tumor & Response To Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Institut Curie, University Paris, Paris, France.
Anne-Sophie HamyResidual Tumor & Response To Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Institut Curie, University Paris, Paris, France.
Florence CoussyResidual Tumor & Response To Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Institut Curie, University Paris, Paris, France.
Amyn KassaraResidual Tumor & Response To Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Institut Curie, University Paris, Paris, France.
Bernard AsselainGINECO Group, Paris, France.
Juliana AnteroInstitute for Biomedical and Epidemiological Research in Sport, France University, EA7329, Paris, France.
Paul De Villèle, Withings, Issy-les-Moulineaux, Paris, France.
Elise DumasResidual Tumor & Response To Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Institut Curie, University Paris, Paris, France.
Nicolas ForstmannInstitute for Biomedical and Epidemiological Research in Sport, France University, EA7329, Paris, France.
Julien GuérinData Office, Institut Curie, Paris, France.
Judicael HottonDepartment of Surgical Oncology, Institut de Cancérologie Jean-Godinot, Reims, France.
Christelle JouannaudDepartment of Medical Oncology, Institut de Cancérologie Jean-Godinot, Reims, France.
Maud MilderData Office, Institut Curie, Paris, France.
Armand LeopoldData Office, Institut Curie, Paris, France.
Adrien SedeaudInstitute for Biomedical and Epidemiological Research in Sport, France University, EA7329, Paris, France.
Pauline SoibinetDepartment of Medical Oncology, Institut de Cancérologie Jean-Godinot, Reims, France.
Jean-François ToussaintInstitute for Biomedical and Epidemiological Research in Sport, France University, EA7329, Paris, France.
Vincent Vercamer, Withings, Issy-les-Moulineaux, Paris, France.
Enora LaasResidual Tumor & Response To Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Institut Curie, University Paris, Paris, France.
Fabien ReyalResidual Tumor & Response To Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Institut Curie, University Paris, Paris, France. fabien.reyal@curie.fr.
Institut Curie · FRInstitut National du Sport, de l'Expertise et de la Performance · FRInserm · FRInstitut Jean Godinot · FRImmunité et Cancer · FRArcagy Gineco · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBreast cancer (BC) has particular characteristics in young women, with diagnosis at more advanced stages, a poorer prognosis and highly aggressive tumors. In NeoFit, we will use an activity tracker to identify and describe various digital profiles (heart rate, physical activity, and sleep patterns) in women below the age of 45 years on neoadjuvant chemotherapy for BC.

methodsNeoFit is a prospective, national, multicenter, single-arm open-label study. It will include 300 women below the age of 45 years treated with neoadjuvant chemotherapy for BC. Participants will be asked to wear a Withing Steel HR activity tracker round the clock for 12 months. The principal assessments will be performed at baseline, at the end of neoadjuvant chemotherapy and at 12 months. We will evaluate clinical parameters, such as toxicity and the efficacy of chemotherapy, together with quality of life, fatigue, and parameters relating to lifestyle and physical activity. The women will complete REDCap form questionnaires via a secure internet link. DISCUSSION: In this study, the use of an activity tracker will enable us to visualize changes in the lifestyle of young women on neoadjuvant chemotherapy for BC, over the course of a one-year period. This exploratory study will provide crucial insight into the digital phenotypes of young BC patients on neoadjuvant chemotherapy and the relationship between these phenotypes and the toxicity and efficacy of treatment. This trial will pave the way for interventional studies involving sleep and physical activity interventions.

trial registrationClinicaltrials.gov identifier: NCT05011721 . Registration date: 18/08/2021.

Indexed as

Breast NeoplasmsNeoadjuvant TherapyAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansMulticenter Studies as TopicProspective StudiesQuality of LifeActivity trackersBreast cancerDigitalNeoadjuvantPrevention

Identifiers

PMID35509030
PMCPMC9069776
OpenAlexW4229002742

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.